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Mitochondrial permeability transition pore
NeurodegenerationMitochondrial permeability transition pore (mPTP) plays a central role in alterations of mitochondrial structure
and function leading to neuronal injury relevant to aging and neurodegenerative diseases including Alzheimer's
disease (AD). mPTP putatively consists of the voltage-dependent anion channel (VDAC), the adenine nucleotide
translocator (ANT) and cyclophilin D (CypD). Reactive oxygen species (ROS) increase intra-cellular calcium and
enhance the formation ofmPTP that leads to neuronal cell death in AD. CypD-dependent mPTP can play a crucial
role in ischemia/reperfusion injury. The interaction of amyloid beta peptide (Aβ) with CypD potentiates mito-
chondrial and neuronal perturbation. This interaction triggers the formation of mPTP, resulting in decreasedmi-
tochondrialmembrane potential, impairedmitochondrial respiration function, increased oxidative stress, release
of cytochrome c, and impaired axonal mitochondrial transport. Thus, the CypD-dependent mPTP is directly
linked to the cellular and synaptic perturbations observed in the pathogenesis of AD. Designing small molecules
to block this interactionwould lessen the effects of Aβ neurotoxicity. This review summarizes the recent progress
onmPTP and its potential therapeutic target for neurodegenerative diseases including AD. This article is part of a
Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.
Published by Elsevier B.V.1. Introduction
Alzheimer's disease (AD) is a chronic neurodegenerative disease,
predominantly affecting the elderly, for which only symptomatic treat-
ments are currently available. There are twopathological features of AD:
abnormal accumulations of amyloid beta peptide (Aβ) and phosphory-
lation of tau protein in the brain. Mitochondrial and synaptic dysfunc-
tion is an early pathological feature of AD brain [1–6]. Recent studies
have highlighted the relation between mitochondrial Aβ accumulation
and synaptic mitochondrial dysfunction. Known Aβ-related mitochon-
drial dysfunctions [7–9] include: excessive reactive oxygen species
(ROS) production [10–13]; disrupted calcium homeostasis [14]; distur-
bance and distribution of mitochondrial dynamics, inducing mito-
chondrial DNA/RNA mutations [15], enhancing vulnerability to other
toxicities,modifying themembranes, and reducing oxidative phosphor-
ylation (Fig. 1). These observations should provide a better understand-
ing of the relationship between mitochondria and AD pathogenesis.
Progressive accumulation ofmitochondrial Aβ in AD brain and in AD
mouse models has been shown to induce mitochondrial malfunction
[4,16–19]. Cyclophilin D (CypD), a peptidyl-prolyl isomerase F, residesfolded Proteins, Mitochondrial
versity of Kansas, Lawrence, KS
.in themitochondrialmatrix andassociateswith the innermitochondrial
membrane during themitochondrialmembrane permeability transition
[20]. CypD plays a central role in opening the mitochondrial membrane
permeability transition pore (mPTP) that leads to cell death. The level of
CypD was signiﬁcantly elevated in neurons in AD-affected regions.
Using surface Plasmon resonance with recombinant human CypD pro-
tein, Aβ binds to CypDduring an in vitro protein–protein interaction. In-
deed, this Aβ-CypD complex was found in Aβ-rich mitochondria from
AD brain and transgenic AD mice [17,21]. CypD deﬁciency (lacking Aβ
binding partner) prevented Aβ-mediated mitochondrial and synaptic
dysfunction [17,21]. Although the precise role of Aβ in mitochondria is
not yet deﬁned, recent reports indicate that interaction ofmitochondrial
Aβ with mitochondrial proteins, Aβ binding alcohol dehydrogenase
(ABAD) and CypD, exacerbates mitochondrial and neuronal stress in
transgenic AD mouse models [16–18,21–23].
Factors like the perturbation of intracellular calcium regulation, the
release of pro-apoptotic factors, regulation in mitochondrial morpholo-
gy, and ROS generation are often associated with mPTP formation.
Increasing calcium concentration has been shown to increase ROS gen-
eration, decrease ATP production, and induce the release of apotogenic
factors followed by swelling of themitochondria [24–27]. In the absence
of CypD, keystone molecules comprising the mPTP, and involved in
Aβ-mediated mitochondrial, neuronal, and synaptic dysfunction are
lessened [17,21]. This knowledge has proven crucial to our understand-
ing of Aβ toxicity and the pathogenesis of AD. Binding appropriate
inhibitors to CypD even in the presence of Ca2+ leads to neuronal
protection.
Fig. 1. Toxicities induced byAβ: Aβ is known to cause neuronal toxicity by severalmechanisms, including increased ROS production, induction of apoptosis, disturbing calciumhomeostasis, and
enhancing the vulnerability of neurons to other toxic substances, etc.
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occur in theADbrain anddiscusses how these abnormalities result in syn-
aptic dysfunction and cell death. Currently available therapeutic strategies
for AD are highlighted, particularly those for mPTP prevention.
2. Mitochondria and mitochondrial permeability transition
pore (mPTP)
Mitochondria are membranous enclosed organelles found in all
eukaryotic cells; they play a vital role in cellular bioenergetics, thermo-
genesis, heme biosynthesis, lipid catabolism, calcium homeostasis, and
other metabolic activities. Furthermore, mitochondria are exclusively
poised to play an essential role in neuronal cell survival or death after
central nervous system (CNS) injury because they are regulators of
both energy metabolism and apoptotic pathways [28–30]. Therefore,
structurally and functionally intact mitochondria are crucial for healthy
cells. A mitochondrion contains outer and inner membranes composed
of phospholipid bilayers and proteins. The two membranes, however,
have different properties. The outer membrane is freely permeable to
small molecules, such as ions and sugars, while the inner membrane
does not contain porins and is highly impermeable to all molecules
[31,32]. Transporters, present in the inner mitochondrial membrane
(IMM), allow the entry of speciﬁc substrates into themitochondrialma-
trix. Hence, it providesmitochondrialmatrix homeostasis by preventing
the free exchange of substances between the matrix and cytosol. Two
major transporters present in the IMMplay an important role in calcium
homeostasis [33–35]. Calcium ATPase helps in the uptake of calcium
into mitochondria, whereas sodium calcium exchanger helps in the
release of calcium into the cytosol frommitochondria. Under the condi-
tions of calcium or phosphate overload and intracellular oxidative
stress, mitochondria efﬂux calcium through mPTP by a transporter-
independent process and thereby activates the apoptotic pathway as
the mitochondria lose their calcium handling ability.
2.1. mPTP as a therapeutic target
The mitochondrial permeability transition is deﬁned as the sudden
increase in the permeability of the IMM to solutes with a molecularmass of less than 1500 Da,which results in the loss ofmembrane poten-
tial (Δψ),mitochondrial swelling, and rupture of the outermitochondri-
al membrane (OMM) [34,36]. The molecular composition of the mPTP
remains a puzzle in spite of extensive interest and thorough studies car-
ried out over the last decades. The mitochondrial permeability transi-
tion is thought to occur after the opening of a mega channel that is
known as the mPTP. Three major proteins are proposed to comprise
the mPTP: the voltage-dependent anion channel (VDAC) present in
the outer membrane, the adenine nucleotide translocator (ANT) located
in the inner membrane, CypD found in the matrix, and other molecules
[37,38]. Under normal conditions, CypD resides in the mitochondrial ma-
trix and the mPTP remains closed.
In the presence of factors acting as permeability transition inducers,
CypD becomes associated with the IMM. This results in the formation of
an ANT channel in the IMM, which in turn increases inner membrane
permeability and opens the mPTP [38]. The channel, formed by VDAC in
the OMM together with ANT, comprises a tunnel-like structure crossing
the mitochondrial membranes, thus connects the mitochondrial matrix
with the cytosol [39,40]. Studies in animal models have shown that
CypD inhibitor Cyclosporine A (CsA), or its non-immunosuppressive ana-
logN-methyl-Val-4-CsA, inhibitsmPTP formation by blocking the interac-
tion of CyPD with the ANT, and as a result the conformational change of
ANT is blocked [41–44]. Bongkrekic acid and atractyloside, are two
other modulators of the ANT andmPTP, which inhibit and induce the in-
duction of the mPTP respectively [45–47].
However, the exact structure of themPTP remains controversial. It is
hypothesized that ANT from the IMM, VDAC from the OMM, the CsA
binding protein CypD from the matrix, and several other proteins
come together to form the pore [26,48–50]. In the recent investigation,
genetic knockout studies challenge the validity of this model by show-
ing that the mPTP still occurs in mitochondria that are deﬁcient in
ANT, VDAC and even CypD, although some properties of the mPTP are
altered [51–54]. Additionally, a recent study suggests that phosphate
carrier (PiC) in IMM is a potential constituent of the mPTP [55]. Leung
and colleagues demonstrated that PiC could form a pore either by itself
or in associationwith ANT, suggesting that PiC but not ANT is the neces-
sary component of themPTP. Also, the study shows that high concentra-
tions of calcium alone can trigger PiC. Interestingly, CypD binding is also
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pore opening. These data may provide an explanation for the failure of
VDAC or ANT ablation to preventmPTP formation, whereas in CypD de-
ﬁcient mitochondria, mPTP induction requires greater calcium levels
and is not completely blocked by CsA treatment.
2.2. Consequences of mPTP formation
The consequence of mPTP pore opening is that all small electrolytes
equilibrate across the IMM, including cofactors and ions. This will not
only lead to the disruption of metabolic gradients between the mito-
chondria and cytosol, including the release of accumulated calcium,
but will also lead to osmotic swelling of mitochondria. The IMM no lon-
ger maintains a barrier to protons which leads to dissipation of the pro-
tonmotive force. The resultant uncoupling of oxidative phosphorylation
prevents mitochondria from generating ATP, leading to ATP depletion
and increased generation of ROS. Mitochondrial swelling may rupture
the OMM by releasing cytochrome c. In turn, cytochrome c initiates cel-
lular apoptosis by activating pro-apoptotic factors. It can therefore be
concluded that massive formation of mPTP under pathological conditions
causes severe mitochondrial injury and cell death. Potential mPTP
blockers include: the immune suppressant Cyclosporin A (CsA) [17,56];
Sanglifehrin A (SfA) [57]; ADP [58]; a non-immunosuppressant deriva-
tive of CsA, N-methyl-Val-4-cyclosporin A (MeValCsA) [59] a non-
immunosuppressive agent, NIM811, 2-aminoethoxydiphenyl borate
(2-APB) [60]; and bongkrekic acid. Available evidence indicates that
CypD is the most important initiating molecule for the mPTP, and that
mPTP formation results in mitochondrial dysfunction, irreversible cell
damage, and cell death.
2.3. Signiﬁcance of mPTP in normal and disease states
AD [17], Parkinson's disease (PD) [61,62], amyotrophic lateral scle-
rosis (ALS) [63,64], and Huntington's disease (HD) [65] are the most
common human adult-onset neurodegenerative diseases. In AD, in-
volvement of themPTP is evidenced by alterations in enzymes involved
in oxidative phosphorylation, oxidative damage, and mitochondrial
binding of Aβ and amyloid precursor protein (APP). Similarly, in PD,
mutations in putative mitochondrial proteins have been identiﬁed and
mitochondrial DNA mutations have been found in neurons in the
substantia nigra. Moreover, changes in ALS occur in mitochondrial re-
spiratory chain enzymes and mitochondrial cell death proteins. In our
published studies [17], we demonstrated that mitochondria isolated
from thehippocampus and temporal lobe of ADpatients showed elevat-
ed CypD levels. Increased CypD expression is predominantly localized in
neurons in these speciﬁc areas of AD patients [17]. Given the positive
correlation of CypD expression to mPTP opening [17,26,64,66], neurons
with increased expression of CypD in AD-affected brain regions would
bemore susceptible tomPTP formation and the resultant consequences.
Likewise, up-regulation of CypD expression in cortical mitochondria
was seen in AD mice overexpressing APP and Aβ (APP mice). As
expected, cortical mitochondria from APP mice demonstrate increased
CypD translocation to the IMM and decreased mitochondrial calcium
buffering capacity, suggesting that mitochondria enriched for Aβ envi-
ronment are susceptible tomPTP formation,which is consistentwith in-
creased CypD expression [17,21].
3. Role of the CypD-dependent mPTP in ischemia
CypD and calcium are well known for their role in the formation of
the mPTP, mitochondrial permeability, and neuronal cell death by acti-
vation of apoptosis. However, the role of CypD in hypoxia-induced is-
chemic brain injury is not well understood. CypD-deﬁcient mouse
studies revealed that CypD-dependent mPTP opening plays a crucial
role in ischemia/reperfusion injury affecting the heart [26,67] and
brain [68], suggesting that the CypD-dependent mPTP is involved inischemia/reperfusion-induced cell death. Hence, CypD and other com-
ponents of the mPTP are important targets for preventing cell damage.
Ischemia/reperfusion injury is a very complex phenomenon, which in-
volves several death mechanisms. Hence, ischemia/reperfusion injury
can be improved by inhibiting apoptosis with caspase inhibitors
[69–71], inhibiting necrosis with Nec1 [72], or blocking the Ask1 path-
way [73]. In vitro cell culture model systems revealed that death mech-
anisms involve caspases, a Nec1 target, and Ask1. The Cyp D-dependent
mPTP does not seem to overlap with each other. Different death mech-
anismsmight operate in a sequential or parallelmanner in the same cell.
Inhibition of one mechanism might have a protective effect. Alterna-
tively, different death mechanisms might act on different cells during
ischemia/reperfusion injury and the dying cells might trigger the
death process in other cells. It is also possible that different cell death
mechanisms are activated by different ischemic conditions. For further
studies of ischemia/reperfusion injury, mice that lack certain cell
death mechanisms, such as CypD-deﬁcient mice and Bax/Bak-deﬁcient
mice, would be useful tools. The CypD-dependent mPTP might also be
involved in other diseases. Mitochondria isolated from the livers of neu-
romuscular disorder of mnd2 mutant mice with mutation of the omi
gene are more susceptible to the mPTP [74]. MND2 mice succumb to
motor neuron disease [75], which might be caused by mPTP formation
occurring at a lower threshold in neuronal mitochondria. Thus, future
studiesmay unveil a role of the CypD-dependentmPTP in the pathogen-
esis of various diseases.3.1. Role of the CypD-dependent mPTP in Aβ-mediated toxicity and
oxidative stress
Signiﬁcant evidence from recent studies shows that Aβ impairs
mPTP function [5,16,18,76,77] by disrupting mitochondrial membrane
potential, and increasing ROS generation, mitochondrial swelling, and
cytochrome c release. We have demonstrated that CypD-deﬁcient neu-
rons are resistant to Aβ-impaired mitochondrial neuronal function. In
fact, CypD-deﬁcient transgenicmAPPmice overexpressingAβ show sig-
niﬁcant improvement inmitochondrial and synaptic function as well as
enhanced learning andmemory compared to singlemAPPmice [17,21].
Potential mechanisms underlying mitochondrial perturbation in the
presence of Aβ are triggering mPTP opening through enhancing CypD
translocation to the inner membrane, thereby increasingmitochondrial
ROS production and decreasing mitochondrial calcium buffering capac-
ity. These data indicate that mPTP formation is augmented in the pres-
ence of Aβ.
Of note, Aβ can increase intracellular calcium and free radical levels,
indirectly affectingmPTP [78]. As a result, this process in turn affects cel-
lular damage primarily through induction of free radical generation and
calcium dysregulation, leading to neuronal injury [79,80]. The mPTP is
strongly induced by calcium and free radicals and, contrarily, mPTP for-
mation further aggravates oxidative stress and calcium perturbation.
Hence, Aβ-mediated perturbation of neuronal calcium metabolism
and ROS generation are possible mechanisms underlying Aβ-induced
mPTP formation [79,81], contributing to mitochondrial and neuronal
degeneration. Furthermore, oxidative and other cellular stresses are
strong inducers of CypD translocation to the IMM [26], and this translo-
cation is a key factor that triggers mPTP opening and formation of Aβ-
CypD complexes. Using surface Plasmon resonance with recombinant
human CypD protein, Aβ binds to CypD during an in vitro protein–
protein interaction. Indeed, this Aβ-CypD complex was found in
Aβ-rich mitochondria from AD brain and transgenic AD mice [17,21].
Additionally, a recent report usingmolecular docking experiments pos-
tulated that Aβ binds with ANT [82]. Both Aβ and oxidative stress have
been shown to synergistically affect MPTP formation, which is critical
for mitochondrial pathology and neuronal dysfunction in AD pathogen-
esis. We therefore propose that mPTP formation is a potential target for
AD therapeutic strategies [82].
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dynamics and motility via Aβ-induction
To better understand the key role of CypD in mPTP function, it was
decided to assess the effect of CypDon Aβ-induced axonalmitochondri-
al trafﬁcking and synaptic damage. Findings revealed that the blockade
of mPTP by CypD depletion rescues axonal mitochondrial trafﬁcking
and protects synapses from Aβ toxicity. Axonal mitochondria are dis-
tributed along axons [83] and decreased axonal mitochondrial density
is amanifestation of disruptedmitochondrial trafﬁcking. Signiﬁcant dif-
ferences are observed between cultured nonTg- and CypD-deﬁcient
hippocampal neurons after exposure to oligomeric Aβ (1–42). NonTg
neurons revealed signiﬁcantly decreased axonal mitochondrial density
but CypD depletion protected axonal mitochondrial density from Aβ
toxicity. Axonal mitochondrial density showed no signiﬁcant changes
in vehicle-treated nonTg neurons when compared to CypD-deﬁcient
neurons [83], suggesting no effect of CypD depletion on axonal mito-
chondrial distribution without Aβ insult. These results indicate that
CypD depletion preserves the organization of axonal mitochondrial dis-
tribution following Aβ insult. Furthermore, neurons lacking CypD are
resistant to Aβ-disrupted PKA/CREB signaling, as shown by increased
PKA activity, phosphorylation of PKA catalytic subunit (PKA C), and
CREB. CypD depletion rescues loss of synapses and improves synaptic
activity [77]. Thus, CypD-dependent signaling pathway (PKA-CREB) is
an important mechanism underlying Aβ- and oxidative stress-induce
synaptic injury.
4. Current CypD inhibitors
CypD, an integral part of the mPTP, belongs to the cyclophilin family
of peptidylprolyl cistrans-isomerases (PPIases) [20]. CypD displays an
important role in the cell response to a variety of noxious stimuli, as it
modulates the opening of the mPTP channel when it translocates toFig. 2. Formation ofmPTP is triggered by twomajor noxious insults: 1. calcium overload in them
ANT leading to the formation ofmPTP alongwith VDAC. This is further facilitatedbyCypD.mPTP
which ﬁnally leads to the release of pro-apoptotic molecules such as cytochrome c into the cyt
leads to the depletion of ATP, which ﬁnally triggers necrotic oncosis. Mitochondria can maintain
Both of these processes are major contributing factors for neuronal cell death in AD. CypD inhi
neuronal cell death.the IMM leading to eventual cell death [17]. A critical event in some
forms of necrotic and apoptotic cell death is the opening of the mPTP
[84,85], the formation of which is widely thought to involve an interac-
tion between theANT and CypD [34]. To date, themost speciﬁc inhibitor
of the mPTP is Cyclosporin A (CsA) [86], which acts by inhibiting the
PPIase activity of CypD [87,88]. CsA lacks clinical signiﬁcance because
of its immunosuppressive effect by inhibiting calcineurin (a calcium de-
pendent protein phosphatase), and inability to pass through the blood–
brain barrier. However, several CsA derivatives have been developed,
including N-Me-Ala-6-cyclosporin A and N-Me-Val-4-cyclosporin
which lack the immunosuppressive effects but are still potent inhibitors
of the PPIase activity of CypD, and thereby antagonize mPTP opening
and apoptosis induction [89–91]. Sanglifehrin A (SfA) is also a recently
developed potent inhibitor of the mPTP; although SfA does not prevent
CyP-D binding to the ANT, it does inhibit its PPIase activity, preventing it
from facilitating the conformational change of the ANT required for pore
formation, thereby inhibiting apoptosis induction [57]. The SfA–CypD
complex has no effect on the calcium-activated protein phosphatase,
calcineurin [92]. All CsA derivatives lack signiﬁcance as therapeuticmol-
ecules because of severe side effects including nephrotoxicity, neuro-
toxicity, and hepatotoxicity, and their poor permeability to the blood–
brain barrier. Azzolin et al. have developed a new class of drugs called
antmanide (AA) from the fungus Amanita phalloides for targeted inhibi-
tion of the CypD PPIase activity, leading tomPTP inhibition and cell pro-
tection from insults that cause pore opening [93]. AA lacks its inhibitory
effects on mitochondria or cells derived from CypD null mice. AA in-
hibits mPTP formation in a CypD independent fashion, which requires
two critical residues in the peptide ring Phe 6, 9. AA also exhibits an ad-
ditive effectwith ubiquinone 0,which inhibitsmPTP opening in isolated
hepatocytes. As a part of developing novel inhibitors of CypD PPIase ac-
tivity, Guo H. et al. have synthesized small molecule quinoxaline deriv-
atives that inhibit mPTP opening [94]. ADP binding to the ANT causes a
conformational change thereby inhibiting mPTP opening. Currentlyitochondrialmatrix, and 2. oxidative stress, which triggers a conformational change in the
opening causesmitochondrial swelling and rupture of the outermitochondrialmembrane,
osol. If the pore opens for a longer period of time, loss of membrane potential occurs that
ATP levels if themPTP opens for a short period of time, which triggers necrotic apoptosis.
bitors have the potential to prevent the formation of mPTP and provide protection against
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molecules with high molecular weights, resulting in poor cell permeabil-
ity and inability to cross the blood–brain barrier. Hence there is a need for
developing new small molecules that can overcome the above problems.
5. Conclusion
Several lines of evidence suggest that aging and age-related neuro-
logical diseases are predominantly associated with mitochondrial dys-
function. Given that mitochondrial and synaptic dysfunction is an
early pathological feature of AD in the brain, targeting mitochondrial
function may be a potential therapeutic strategy for early stages of AD
treatment. Mitochondrial dysfunction leads to the increased generation
of ROS, abnormal protein–protein interactions, and decreased mito-
chondrial ATP production. Increased production of ROS with accompa-
nying compromised mitochondrial function results in damage to
neurons following formation of the mPTP. Several other factors includ-
ing increased intracellular calcium, Aβ, and CypD also play an important
role in the formation of mPTP, which leads tomitochondrial and neuro-
nal degeneration. Thus, inhibition of mPTP formation by blocking CypD
is a rational target for potential therapeutic AD strategies. Because the
currently available CypD inhibitors are large molecules with high mo-
lecular weights that have difﬁculty crossing the blood–brain barrier,
and have low cell permeability, there is currently a need indevelopment
of small, drug-like, low-molecularweight compounds that inhibit CypD,
thereby improving mitochondrial and neuronal function relevant to
neurodegenerative diseases including AD (Fig. 2).
Acknowledgements
This study is supported by grants from the National Institute of
Aging (R37AG037319) and the National Institute of General Medical
Science (R01GM095355).
References
[1] H. Du, L. Guo, S. Yan, A.A. Sosunov, G.M. McKhann, S.S. Yan, Early deﬁcits in synaptic
mitochondria in an Alzheimer's disease mouse model, Proc. Natl. Acad. Sci. U. S. A.
107 (2010) 18670–18675.
[2] H. Du, L. Guo, S.S. Yan, Synaptic mitochondrial pathology in Alzheimer's disease,
Antioxid. Redox Signal. 16 (2011) 1467–1475.
[3] J.X. Chen, S.S. Yan, Role of mitochondrial amyloid-beta in Alzheimer's disease,
J. Alzheimers Dis. 20 (Suppl. 2) (2010) S569–S578.
[4] C. Caspersen, N. Wang, J. Yao, A. Sosunov, X. Chen, J.W. Lustbader, H.W. Xu, D. Stern,
G.McKhann, S.D. Yan, Mitochondrial Abeta: a potential focal point for neuronal met-
abolic dysfunction in Alzheimer's disease, FASEB J. 19 (2005) 2040–2041.
[5] P.H. Reddy, M.F. Beal, Amyloid beta, mitochondrial dysfunction and synaptic damage:
implications for cognitive decline in aging and Alzheimer's disease, Trends Mol. Med.
14 (2008) 45–53.
[6] M.T. Lin, M.F. Beal, Alzheimer's APP mangles mitochondria, Nat. Med. 12 (2006)
1241–1243.
[7] N. Sergeant, A. Wattez, M. Galvan-valencia, A. Ghestem, J.P. David, J. Lemoine, P.E.
Sautiere, J. Dachary, J.P. Mazat, J.C. Michalski, J. Velours, R. Mena-Lopez, A. Delacourte,
Association of ATP synthase alpha-chain with neuroﬁbrillary degeneration in
Alzheimer's disease, Neuroscience 117 (2003) 293–303.
[8] L. Tillement, L. Lecanu, W. Yao, J. Greeson, V. Papadopoulos, The spirostenol (22R,
25R)-20alpha-spirost-5-en-3beta-yl hexanoate blocks mitochondrial uptake of
Abeta in neuronal cells and prevents Abeta-induced impairment of mitochondrial
function, Steroids 71 (2006) 725–735.
[9] G. Csordas, A.P. Thomas, G. Hajnoczky, Quasi-synaptic calcium signal transmission
between endoplasmic reticulum and mitochondria, EMBO J. 18 (1999) 96–108.
[10] J.F. Turrens, Mitochondrial formation of reactive oxygen species, J. Physiol. 552
(2003) 335–344.
[11] Y.P. Li, A.F. Bushnell, C.M. Lee, L.S. Perlmutter, S.K. Wong, Beta-amyloid induces ap-
optosis in human-derived neurotypic SH-SY5Y cells, Brain Res. 738 (1996) 196–204.
[12] S. Estus, H.M. Tucker, C. van Rooyen, S. Wright, E.F. Brigham, M. Wogulis, R.E. Rydel,
Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concom-
itant “apoptotic” pattern of gene induction, J. Neurosci. 17 (1997) 7736–7745.
[13] B. Sheng, K. Gong, Y. Niu, L. Liu, Y. Yan, G. Lu, L. Zhang, M. Hu, N. Zhao, X. Zhang, P.
Tang, Y. Gong, Inhibition of gamma-secretase activity reduces Abeta production, re-
duces oxidative stress, increases mitochondrial activity and leads to reduced vulner-
ability to apoptosis: implications for the treatment of Alzheimer's disease, Free
Radic. Biol. Med. 46 (2009) 1362–1375.
[14] L. Tillement, L. Lecanu, V. Papadopoulos, Alzheimer's disease: effects of beta-amyloid
on mitochondria, Mitochondrion 11 (2011) 13–21.[15] A. Nunomura, T. Hofer, P.I. Moreira, R.J. Castellani, M.A. Smith, G. Perry, RNA
oxidation in Alzheimer disease and related neurodegenerative disorders, Acta
Neuropathol. 118 (2009) 151–166.
[16] K. Takuma, J. Yao, J. Huang, H. Xu, X. Chen, J. Luddy, A.C. Trillat, D.M. Stern, O.
Arancio, S.S. Yan, ABAD enhances Abeta-induced cell stress via mitochondrial dys-
function, FASEB J. 19 (2005) 597–598.
[17] H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H.
Zhang, J.D. Molkentin, F.J. Gunn-Moore, J.P. Vonsattel, O. Arancio, J.X. Chen, S.D.
Yan, Cyclophilin D deﬁciency attenuates mitochondrial and neuronal perturbation
and ameliorates learning and memory in Alzheimer's disease, Nat. Med. 14 (2008)
1097–1105.
[18] J.W. Lustbader, M. Cirilli, C. Lin, H.W. Xu, K. Takuma, N. Wang, C. Caspersen, X. Chen,
S. Pollak, M. Chaney, F. Trinchese, S. Liu, F. Gunn-Moore, L.F. Lue, D.G. Walker, P.
Kuppusamy, Z.L. Zewier, O. Arancio, D. Stern, S.S. Yan, H. Wu, ABAD directly links
Abeta to mitochondrial toxicity in Alzheimer's disease, Science 304 (2004) 448–452.
[19] M. Manczak, T.S. Anekonda, E. Henson, B.S. Park, J. Quinn, P.H. Reddy, Mitochondria
are a direct site of A beta accumulation in Alzheimer's disease neurons: implications
for free radical generation and oxidative damage in disease progression, Hum. Mol.
Genet. 15 (2006) 1437–1449.
[20] A. Galat, S.M.Metcalfe, Peptidylproline cis/trans isomerases, Prog. Biophys. Mol. Biol.
63 (1995) 67–118.
[21] H. Du, L. Guo, W. Zhang, M. Rydzewska, S. Yan, Cyclophilin D deﬁciency improves
mitochondrial function and learning/memory in aging Alzheimer disease mouse
model, Neurobiol. Aging 32 (2011) 398–406.
[22] K.R. Valasani, G. Hu, M.O. Chaney, S.S. Yan, Structure-Based Design and Synthesis
of Benzothiazole Phosphonate Analogues with Inhibitors of Human ABAD-Aβ
for Treatment of Alzheimer's disease, Chem Biol Drug Des. 81 (2) (2013 Feb)
238–249.
[23] K.R. Valasani, M.O. Chaney, V.W. Day, S. Shidu Yan, Acetylcholinesterase inhibitors:
structure based design, synthesis, pharmacophore modeling, and virtual screening,
J Chem Inf Model 53 (8) (2013 Aug) 2033–2046.
[24] G. Petrosillo, F.M. Ruggiero, M. Pistolese, G. Paradies, Ca2+-induced reactive oxygen
species production promotes cytochrome c release from rat liver mitochondria via
mitochondrial permeability transition (MPT)-dependent and MPT-independent
mechanisms: role of cardiolipin, J. Biol. Chem. 279 (2004) 53103–53108.
[25] T.R. Rosenstock, A.C. Carvalho, A. Jurkiewicz, R. Frussa-Filho, S.S. Smaili, Mitochon-
drial calcium, oxidative stress and apoptosis in a neurodegenerative disease model
induced by 3-nitropropionic acid, J. Neurochem. 88 (2004) 1220–1228.
[26] C.P. Baines, R.A. Kaiser, N.H. Purcell, N.S. Blair, H. Osinska, M.A. Hambleton, E.W.
Brunskill, M.R. Sayen, R.A. Gottlieb, G.W. Dorn, J. Robbins, J.D. Molkentin, Loss of
cyclophilin D reveals a critical role for mitochondrial permeability transition in
cell death, Nature 434 (2005) 658–662.
[27] H. Du, S.S. Yan, Mitochondrial permeability transition pore in Alzheimer's disease:
cyclophilin D and amyloid beta, Biochim. Biophys. Acta 1802 (2010) 198–204.
[28] G. Fiskum, Mitochondrial participation in ischemic and traumatic neural cell death,
J. Neurotrauma 17 (2000) 843–855.
[29] T. Wieloch, Mitochondrial involvement in acute neurodegeneration, IUBMB Life 52
(2001) 247–254.
[30] H. Friberg, T. Wieloch, Mitochondrial permeability transition in acute neuro-
degeneration, Biochimie 84 (2002) 241–250.
[31] H. Kroner, Ca2+ ions, an allosteric activator of calcium uptake in rat liver mitochon-
dria, Arch. Biochem. Biophys. 251 (1986) 525–535.
[32] E.J. Grifﬁths, Mitochondrial calcium transport in the heart: physiological and patho-
logical roles, J. Mol. Cell. Cardiol. 46 (2009) 789–803.
[33] G.P. McStay, S.J. Clarke, A.P. Halestrap, Role of critical thiol groups on the matrix sur-
face of the adenine nucleotide translocase in the mechanism of the mitochondrial
permeability transition pore, Biochem. J. 367 (2002) 541–548.
[34] A.P. Halestrap, G.P. McStay, S.J. Clarke, The permeability transition pore complex:
another view, Biochimie 84 (2002) 153–166.
[35] A.P. Halestrap, The mitochondrial permeability transition: its molecular mechanism
and role in reperfusion injury, Biochem. Soc. Symp. 66 (1999) 181–203.
[36] M. Zoratti, I. Szabo, The mitochondrial permeability transition, Biochim. Biophys.
Acta 1241 (1995) 139–176.
[37] P.G. Sullivan, A.G. Rabchevsky, P.C. Waldmeier, J.E. Springer, Mitochondrial perme-
ability transition in CNS trauma: cause or effect of neuronal cell death? J. Neurosci.
Res. 79 (2005) 231–239.
[38] Y. Tsujimoto, S. Shimizu, Role of the mitochondrial membrane permeability transi-
tion in cell death, Apoptosis 12 (2007) 835–840.
[39] I. Szabo, V. De Pinto, M. Zoratti, The mitochondrial permeability transition pore may
comprise VDAC molecules. II. The electrophysiological properties of VDAC are
compatible with those of the mitochondrial megachannel, FEBS Lett. 330 (1993)
206–210.
[40] A.P. Halestrap, C.P. Connern, E.J. Grifﬁths, P.M. Kerr, Cyclosporin A binding to mito-
chondrial cyclophilin inhibits the permeability transition pore and protects hearts
from ischaemia/reperfusion injury, Mol. Cell. Biochem. 174 (1997) 167–172.
[41] K.M. Broekemeier, M.E. Dempsey, D.R. Pfeiffer, Cyclosporin A is a potent inhibitor of
the innermembrane permeability transition in liver mitochondria, J. Biol. Chem. 264
(1989) 7826–7830.
[42] I. Szabo, M. Zoratti, The giant channel of the inner mitochondrial membrane is
inhibited by cyclosporin A, J. Biol. Chem. 266 (1991) 3376–3379.
[43] C.P. Connern, A.P. Halestrap, Recruitment of mitochondrial cyclophilin to the mito-
chondrial inner membrane under conditions of oxidative stress that enhance the
opening of a calcium-sensitive non-speciﬁc channel, Biochem. J. 302 (Pt 2) (1994)
321–324.
[44] K.M. Broekemeier, D.R. Pfeiffer, Inhibition of the mitochondrial permeability transi-
tion by cyclosporin A during long time frame experiments: relationship between
1272 V.K. Rao et al. / Biochimica et Biophysica Acta 1842 (2014) 1267–1272pore opening and the activity of mitochondrial phospholipases, Biochemistry 34
(1995) 16440–16449.
[45] N. Brustovetsky, J.M. Dubinsky, Dual responses of CNS mitochondria to elevated cal-
cium, J. Neurosci. 20 (2000) 103–113.
[46] D. Jiang, P.G. Sullivan, S.L. Sensi, O. Steward, J.H. Weiss, Zn(2+) induces permeabil-
ity transition pore opening and release of pro-apoptotic peptides from neuronal mi-
tochondria, J. Biol. Chem. 276 (2001) 47524–47529.
[47] P.G. Sullivan, J.E. Springer, E.D. Hall, S.W. Scheff, Mitochondrial uncoupling as a ther-
apeutic target following neuronal injury, J. Bioenerg. Biomembr. 36 (2004) 353–356.
[48] C.P. Connern, A.P. Halestrap, Chaotropic agents and increased matrix volume en-
hance binding of mitochondrial cyclophilin to the inner mitochondrial membrane
and sensitize the mitochondrial permeability transition to [Ca2+], Biochemistry 35
(1996) 8172–8180.
[49] Y. Zheng, Y. Shi, C. Tian, C. Jiang, H. Jin, J. Chen, A. Almasan, H. Tang, Q. Chen, Essen-
tial role of the voltage-dependent anion channel (VDAC) in mitochondrial perme-
ability transition pore opening and cytochrome c release induced by arsenic
trioxide, Oncogene 23 (2004) 1239–1247.
[50] C.R. Pestana, C.H. Silva, G.L. Pardo-Andreu, F.P. Rodrigues, A.C. Santos, S.A. Uyemura, C.
Curti, Ca(2+) binding to c-state of adenine nucleotide translocase (ANT)-surrounding
cardiolipins enhances (ANT)-Cys(56) relative mobility: a computational-based mito-
chondrial permeability transition study, Biochim. Biophys. Acta 1787 (2009) 176–182.
[51] P. Bernardi, M. Forte, The mitochondrial permeability transition pore, Novartis
Found. Symp. 287 (2007) 157–164(discussion 164–159).
[52] M. Juhaszova, S. Wang, D.B. Zorov, H.B. Nuss, M. Gleichmann, M.P. Mattson, S.J.
Sollott, The identity and regulation of the mitochondrial permeability transition
pore: where the known meets the unknown, Ann. N. Y. Acad. Sci. 1123 (2008)
197–212.
[53] J.E. Kokoszka, K.G. Waymire, S.E. Levy, J.E. Sligh, J. Cai, D.P. Jones, G.R. MacGregor,
D.C. Wallace, The ADP/ATP translocator is not essential for the mitochondrial
permeability transition pore, Nature 427 (2004) 461–465.
[54] A. Krauskopf, O. Eriksson, W.J. Craigen, M.A. Forte, P. Bernardi, Properties of the per-
meability transition in VDAC1(−/−) mitochondria, Biochim. Biophys. Acta 1757
(2006) 590–595.
[55] A.W. Leung, P. Varanyuwatana, A.P. Halestrap, The mitochondrial phosphate carrier
interacts with cyclophilin D and may play a key role in the permeability transition,
J. Biol. Chem. 283 (2008) 26312–26323.
[56] M.J. Hansson, T. Persson, H. Friberg, M.F. Keep, A. Rees, T. Wieloch, E. Elmer, Power-
ful cyclosporin inhibition of calcium-induced permeability transition in brain mito-
chondria, Brain Res. 960 (2003) 99–111.
[57] S.J. Clarke, G.P. McStay, A.P. Halestrap, Sanglifehrin A acts as a potent inhibitor of the
mitochondrial permeability transition and reperfusion injury of the heart by binding
to cyclophilin-D at a different site from cyclosporin A, J. Biol. Chem. 277 (2002)
34793–34799.
[58] A.P. Halestrap, K.Y. Woodﬁeld, C.P. Connern, Oxidative stress, thiol reagents, and
membrane potential modulate the mitochondrial permeability transition by affect-
ing nucleotide binding to the adenine nucleotide translocase, J. Biol. Chem. 272
(1997) 3346–3354.
[59] G. Zenke, U. Strittmatter, S. Fuchs, V.F. Quesniaux, V. Brinkmann, W. Schuler, M. Zurini,
A. Enz, A. Billich, J.J. Sanglier, T. Fehr, Sanglifehrin A, a novel cyclophilin-binding
compound showing immunosuppressive activity with a new mechanism of action,
J. Immunol. 166 (2001) 7165–7171.
[60] C. Chinopoulos, A.A. Starkov, G. Fiskum, Cyclosporin A-insensitive permeability tran-
sition in brain mitochondria: inhibition by 2-aminoethoxydiphenyl borate, J. Biol.
Chem. 278 (2003) 27382–27389.
[61] S. Gandhi, A. Wood-Kaczmar, Z. Yao, H. Plun-Favreau, E. Deas, K. Klupsch, J.
Downward, D.S. Latchman, S.J. Tabrizi, N.W. Wood, M.R. Duchen, A.Y. Abramov,
PINK1-associated Parkinson's disease is caused by neuronal vulnerability to
calcium-induced cell death, Mol. Cell 33 (2009) 627–638.
[62] H.L. Wang, A.H. Chou, T.H. Yeh, A.H. Li, Y.L. Chen, Y.L. Kuo, S.R. Tsai, S.T. Yu, PINK1
mutants associatedwith recessive Parkinson's disease are defective in inhibiting mi-
tochondrial release of cytochrome c, Neurobiol. Dis. 28 (2007) 216–226.
[63] L.J. Martin, B. Gertz, Y. Pan, A.C. Price, J.D. Molkentin, Q. Chang, The mitochondrial
permeability transition pore in motor neurons: involvement in the pathobiology
of ALS mice, Exp. Neurol. 218 (2009) 333–346.
[64] J. Karlsson, K.S. Fong, M.J. Hansson, E. Elmer, K. Csiszar, M.F. Keep, Life span exten-
sion and reduced neuronal death after weekly intraventricular cyclosporin injec-
tions in the G93A transgenic mouse model of amyotrophic lateral sclerosis,
J. Neurosurg. 101 (2004) 128–137.
[65] N. Brustovetsky, T. Brustovetsky, K.J. Purl, M. Capano, M. Crompton, J.M. Dubinsky,
Increased susceptibility of striatal mitochondria to calcium-induced permeability
transition, J. Neurosci. 23 (2003) 4858–4867.
[66] M.R. Brown, P.G. Sullivan, J.W. Geddes, Synaptic mitochondria are more susceptible
to Ca2+ overload than nonsynaptic mitochondria, J. Biol. Chem. 281 (2006)
11658–11668.
[67] T. Nakagawa, S. Shimizu, T. Watanabe, O. Yamaguchi, K. Otsu, H. Yamagata, H.
Inohara, T. Kubo, Y. Tsujimoto, Cyclophilin D-dependent mitochondrial permeability
transition regulates some necrotic but not apoptotic cell death, Nature 434 (2005)
652–658.
[68] A.C. Schinzel, O. Takeuchi, Z. Huang, J.K. Fisher, Z. Zhou, J. Rubens, C. Hetz, N.N.
Danial, M.A. Moskowitz, S.J. Korsmeyer, Cyclophilin D is a component of mitochon-
drial permeability transition andmediates neuronal cell death after focal cerebral is-
chemia, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12005–12010.[69] Y. Cheng, M. Deshmukh, A. D'Costa, J.A. Demaro, J.M. Gidday, A. Shah, Y. Sun, M.F.
Jacquin, E.M. Johnson, D.M. Holtzman, Caspase inhibitor affords neuroprotection
with delayed administration in a rat model of neonatal hypoxic–ischemic brain in-
jury, J. Clin. Invest. 101 (1998) 1992–1999.
[70] J. Chen, T. Nagayama, K. Jin, R.A. Stetler, R.L. Zhu, S.H. Graham, R.P. Simon, Induction
of caspase-3-like proteasemaymediate delayed neuronal death in the hippocampus
after transient cerebral ischemia, J. Neurosci. 18 (1998) 4914–4928.
[71] D. Xu, Y. Bureau, D.C. McIntyre, D.W. Nicholson, P. Liston, Y. Zhu, W.G. Fong, S.J.
Crocker, R.G. Korneluk, G.S. Robertson, Attenuation of ischemia-induced cellular
and behavioral deﬁcits by X chromosome-linked inhibitor of apoptosis protein
overexpression in the rat hippocampus, J. Neurosci. 19 (1999) 5026–5033.
[72] A. Degterev, Z. Huang,M. Boyce, Y. Li, P. Jagtap, N.Mizushima, G.D. Cuny, T.J.Mitchison,
M.A. Moskowitz, J. Yuan, Chemical inhibitor of nonapoptotic cell deathwith therapeu-
tic potential for ischemic brain injury, Nat. Chem. Biol. 1 (2005) 112–119.
[73] T. Watanabe, K. Otsu, T. Takeda, O. Yamaguchi, S. Hikoso, K. Kashiwase, Y. Higuchi, M.
Taniike, A. Nakai, Y. Matsumura, K. Nishida, H. Ichijo, M. Hori, Apoptosis signal-
regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic
cardiomyocyte death, Biochem. Biophys. Res. Commun. 333 (2005) 562–567.
[74] J.M. Jones, P. Datta, S.M. Srinivasula,W. Ji, S. Gupta, Z. Zhang, E. Davies, G. Hajnoczky,
T.L. Saunders, M.L. Van Keuren, T. Fernandes-Alnemri, M.H. Meisler, E.S. Alnemri,
Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of
mnd2 mutant mice, Nature 425 (2003) 721–727.
[75] J.M. Jones, R.L. Albin, E.L. Feldman, K. Simin, T.G. Schuster, W.A. Dunnick, J.T. Collins,
C.E. Chrisp, B.A. Taylor, M.H. Meisler, mnd2: a newmouse model of inherited motor
neuron disease, Genomics 16 (1993) 669–677.
[76] Y. Rui, P. Tiwari, Z. Xie, J.Q. Zheng, Acute impairment of mitochondrial trafﬁcking by
beta-amyloid peptides in hippocampal neurons, J. Neurosci. 26 (2006) 10480–10487.
[77] H. Du, L. Guo, X. Wu, A.A. Sosunov, G.M. McKhann, J.X. Chen, S.S. Yan, Cyclophilin D
deﬁciency rescues Abeta-impaired PKA/CREB signaling and alleviates synaptic de-
generation, Biochim. Biophys. Acta (2013)(pii: S0925-4439(13)00078-1).
[78] S.L. Siedlak, G. Casadesus, K.M. Webber, M.A. Pappolla, C.S. Atwood, M.A. Smith, G.
Perry, Chronic antioxidant therapy reduces oxidative stress in a mouse model of
Alzheimer's disease, Free Radic. Res. 43 (2009) 156–164.
[79] J.H. Chin, F.W. Tse, K. Harris, J.H. Jhamandas, Beta-amyloid enhances intracellular
calcium rises mediated by repeated activation of intracellular calcium stores and
nicotinic receptors in acutely dissociated rat basal forebrain neurons, Brain Cell
Biol. 35 (2006) 173–186.
[80] C. Schoneich, D. Pogocki, G.L. Hug, K. Bobrowski, Free radical reactions of methio-
nine in peptides: mechanisms relevant to beta-amyloid oxidation and Alzheimer's
disease, J. Am. Chem. Soc. 125 (2003) 13700–13713.
[81] S. Morais Cardoso, R.H. Swerdlow, C.R. Oliveira, Induction of cytochrome c-mediated
apoptosis by amyloid beta 25–35 requires functional mitochondria, Brain Res. 931
(2002) 117–125.
[82] P. Singh, S. Suman, S. Chandna, T.K. Das, Possible role of amyloid-beta, adenine nu-
cleotide translocase and cyclophilin-D interaction in mitochondrial dysfunction of
Alzheimer's disease, Bioinformation 3 (2009) 440–445.
[83] L. Guo, H. Du, S. Yan, X. Wu, G.M. McKhann, J.X. Chen, S.S. Yan, Cyclophilin D deﬁ-
ciency rescues axonal mitochondrial transport in Alzheimer's neurons, PLoS One 8
(2013) e54914.
[84] J.C. Martinou, D.R. Green, Breaking themitochondrial barrier, Nat. Rev. Mol. Cell Biol.
2 (2001) 63–67.
[85] P. Bernardi, V. Petronilli, F. Di Lisa, M. Forte, A mitochondrial perspective on cell
death, Trends Biochem. Sci. 26 (2001) 112–117.
[86] M. Crompton, H. Ellinger, A. Costi, Inhibition by cyclosporin A of a Ca2+-dependent
pore in heart mitochondria activated by inorganic phosphate and oxidative stress,
Biochem. J. 255 (1988) 357–360.
[87] A. Tanveer, S. Virji, L. Andreeva, N.F. Totty, J.J. Hsuan, J.M. Ward, M. Crompton, In-
volvement of cyclophilin D in the activation of a mitochondrial pore by Ca2+ and
oxidant stress, Eur. J. Biochem. 238 (1996) 166–172.
[88] E.J. Grifﬁths, A.P. Halestrap, Further evidence that cyclosporin A protects mitochon-
dria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomer-
ase. Implications for the immunosuppressive and toxic effects of cyclosporin,
Biochem. J. 274 (Pt 2) (1991) 611–614.
[89] E.J. Grifﬁths, A.P. Halestrap, Mitochondrial non-speciﬁc pores remain closed during
cardiac ischaemia, but open upon reperfusion, Biochem. J. 307 (Pt 1) (1995) 93–98.
[90] A. Nicolli, E. Basso, V. Petronilli, R.M. Wenger, P. Bernardi, Interactions of cyclophilin
with the mitochondrial inner membrane and regulation of the permeability transi-
tion pore, and cyclosporin A-sensitive channel, J. Biol. Chem. 271 (1996) 2185–2192.
[91] L. Khaspekov, H. Friberg, A. Halestrap, I. Viktorov, T. Wieloch, Cyclosporin A and its
nonimmunosuppressive analogue N-Me-Val-4-cyclosporin A mitigate glucose/oxygen
deprivation-induced damage to rat cultured hippocampal neurons, Eur. J. Neurosci.
11 (1999) 3194–3198.
[92] A.P. Halestrap, S.J. Clarke, S.A. Javadov, Mitochondrial permeability transition pore
opening during myocardial reperfusion—a target for cardioprotection, Cardiovasc.
Res. 61 (2004) 372–385.
[93] L. Azzolin, N. Antolini, A. Calderan, P. Ruzza, M. Sciacovelli, O. Marin, S. Mammi, P.
Bernardi, A. Rasola, Antamanide, a derivative of Amanita phalloides, is a novel inhibitor
of the mitochondrial permeability transition pore, PLoS One 6 (2011) e16280.
[94] H.X. Guo, F. Wang, K.Q. Yu, J. Chen, D.L. Bai, K.X. Chen, X. Shen, H.L. Jiang, Novel
cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity
against rat mitochondrial swelling and Ca2+ uptake/release, Acta Pharmacol. Sin.
26 (2005) 1201–1211.
